BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.52 USD
-0.33 (-4.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $7.51 -0.01 (-0.13%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
BioCryst Pharmaceuticals, Inc. [BCRX]
Reports for Purchase
Showing records 81 - 100 ( 176 total )
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q Preview; Affirm Buy
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rapivab Clinical Data at ICAAC Reinforces Approvability; Affirm Buy
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Officially Joins the Race to Treat the Ebola virus
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
NIAID Funding Stresses Need for Hemorrhagic Fever Antivirals
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Reports 2Q''14 EPS; Expecting OPuS-2 Start by YE14
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Looking Towards OPuS-2 Trial Initiation in 4Q14; Affirm Buy
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Robust OPuS-1 Results Validates Oral Prophylaxis for HAE; Target to $20
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Impressive Data with BCX4161 in OPuS-1 Study
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q14 Recap - Pivotal Catalyst Next Month; Affirm Buy
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Reports 1Q''14 EPS; Reiterating Market Outperform
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Initiating coverage with a Market Outperform and a $15 one-year price target.
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C